Human VSTM4 Alexa Fluor® 700-conjugated Antibody

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Background: VSTM4

V-set and transmembrane domain-containing protein 4 (VSTM4) is a single-pass type I membrane protein in the immunoglobulin superfamily. Human VSTM4 is synthesized as a 320 amino acid (aa) precursor that contains a 23 aa signal sequence, 157 aa extracellular region, 21 aa TM domain, and 119 aa cytoplasmic tail. In humans, part of the extracellular region is cleaved into a 50 aa secreted peptide (aa 55-104) compared to mouse, which is cleaved into a 49 aa peptide (aa 55-103) (1). Because of its role in enhancing L-type voltage-gated calcium channel (L-VGCC) currents in photoreceptors, this peptide was named peptide Lv (1). Peptide Lv is expressed in the central nervous system and a variety of organs including spleen, intestine, retina, and lung (1, 2). The peptide may have possible roles in regulating the cardiovascular system and L-VGCC dependent neural plasticity (1, 2). Human VSTM4 gene is located on chromosome 10, which may be linked to late-onset Alzheimer's disease (3). Down-regulation of VSTM4 increased tamoxifen sensitivity and suppressed growth in cultured breast cancer cells (4). Within the ECD, human VSTM4 shares 87% and 85% aa sequence identity with mouse and rat VSTM4, respectively. The biological functions of VSTM4 remain unknown. Our in-house data show that VSTM4 inhibits the human T cell activation, including anti-CD3 induced IL-2 and IFN-gamma secretion, and T cell proliferation.

Product Datasheets

Related Research Areas

• Search Immune Checkpoint Targets